ALK maintains China bet despite geopolitical unrest

Front lines between China and the Western world have gotten more pronounced recently. Despite this, Danish allergy company ALK is ramping up its activities in the communist-ruled country with double-digit investments this year. ”China is a huge opportunity for us,” CEO Carsten Hellmann tells MedWatch.

Carsten Hellmann, CEO of ALK | Photo: ALK / PR

In recent times, a string of Danish life science firms has been worried over rising geopolitical tensions between Western countries and China.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs